Mesa Laboratories (NASDAQ:MLAB - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.
Other analysts also recently issued reports about the company. Wells Fargo & Company upgraded Mesa Laboratories from an "underweight" rating to an "equal weight" rating and cut their target price for the company from $100.00 to $67.00 in a research note on Thursday, August 7th. Wall Street Zen cut Mesa Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Zacks Research upgraded shares of Mesa Laboratories from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average target price of $67.00.
Read Our Latest Research Report on Mesa Laboratories
Mesa Laboratories Price Performance
Shares of NASDAQ:MLAB opened at $70.75 on Wednesday. The business has a fifty day moving average price of $67.29 and a 200-day moving average price of $91.62. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.66 and a quick ratio of 0.47. The company has a market capitalization of $389.13 million, a PE ratio of -505.36 and a beta of 0.86. Mesa Laboratories has a 1-year low of $55.45 and a 1-year high of $155.12.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in MLAB. GAMMA Investing LLC boosted its position in Mesa Laboratories by 14,805.8% in the 1st quarter. GAMMA Investing LLC now owns 18,036 shares of the medical instruments supplier's stock valued at $2,140,000 after buying an additional 17,915 shares during the period. Rhumbline Advisers increased its stake in shares of Mesa Laboratories by 4.4% during the first quarter. Rhumbline Advisers now owns 13,628 shares of the medical instruments supplier's stock valued at $1,617,000 after buying an additional 570 shares during the period. SG Americas Securities LLC lifted its stake in Mesa Laboratories by 18.7% in the first quarter. SG Americas Securities LLC now owns 2,461 shares of the medical instruments supplier's stock worth $292,000 after acquiring an additional 388 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Mesa Laboratories by 13.8% during the first quarter. Principal Financial Group Inc. now owns 43,659 shares of the medical instruments supplier's stock valued at $5,181,000 after purchasing an additional 5,300 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Mesa Laboratories by 2.7% in the 1st quarter. Bank of New York Mellon Corp now owns 54,767 shares of the medical instruments supplier's stock valued at $6,499,000 after acquiring an additional 1,463 shares during the period. Hedge funds and other institutional investors own 90.60% of the company's stock.
Mesa Laboratories Company Profile
(
Get Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
